Literature DB >> 11098342

Seizure possibly associated with fluvoxamine.

K Y Kim1, J M Craig, J M Hawley.   

Abstract

OBJECTIVE: To inform clinicians of the possibility that seizures due to therapeutic doses of fluvoxamine may not be as rare as previously considered. CASE
SUMMARY: A 49-year-old white man with schizoaffective disorder and a past history of seizures secondary to head trauma had been seizure-free for approximately 10 years. Fluvoxamine therapy was begun due to increasing obsessive-compulsive behavior. Despite receiving anticonvulsants for his mood disorder, the patient had a breakthrough seizure. There were no underlying medical conditions that might have induced this seizure. No further seizures occurred after he was placed on a higher dosage of the anticonvulsants. The obsessive-compulsive behavior improved considerably as a result of fluvoxamine treatment. DISCUSSION: The patient presented here developed a seizure with a therapeutic dosage of fluvoxamine; seizures associated with this agent have occurred more often with overdose. Multiple factors such as a prior history of seizures, head trauma, and concurrent treatment with other psychotropic agents are considered in this case report.
CONCLUSIONS: Despite the relatively safe and benign adverse effect profile of the selective serotonin-reuptake inhibitors such as fluvoxamine, clinicians should be cautious about seizures as an adverse effect, especially when the patient has even a remote history of seizure or head trauma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11098342     DOI: 10.1345/aph.10134

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis.

Authors:  Dena Firouzabadi; Fatemeh Kheshti; Saeed Abdollahifard; Erfan Taherifard; Mohammad Reza Kheshti
Journal:  Health Sci Rep       Date:  2022-10-17

Review 2.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.